<DOC>
	<DOCNO>NCT00250822</DOCNO>
	<brief_summary>To determine primary end point response rate combination Gemcitabine Oxaliplatin ( Gem-Ox ) treatment hepatocellular carcinoma ( HCC ) patient platelet count great 100,000 per microliter single arme Phase II trial . To determine toxicity profile regimen To determine effect treatment patient survival , time treatment failure , time ot progression , time response .</brief_summary>
	<brief_title>Gemcitabine Oxaliplatin Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter</brief_title>
	<detailed_description>The treatment plan two-step design . Day 1 pt receive Gemcitabine IV Day 2 pt receive Oxaliplatin IV . This treatment cycle repeat approximately every 28 day . Subsequent treatment cycle dosage base toxicity diary lab work result . CT scan repeat every 2 treatment cycle . Continuation study dependent upon tumor response .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>All patient 18 year age old , hepatocellular carcinoma eligible . Patients must life expectancy least 12 week . Patients must ECOG performance status 02 . Patients must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 cells/mm3 platelet count &gt; 100,000/mm3 absence regular red blood cell transfusion requirement . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . There must one measurable lesion accord RECIST criterion prior radiation treatment . Patients symptomatic brain metastasis adequately definitively treat radiation and/or surgical resection exclude study . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial . Life expectancy le 12 week . Serious , uncontrolled concurrent infection ( ) Any prior treatment , Gemcitabine Oxaliplatin . Completion previous chemotherapy regimen less 4 week , prior start study persistence prior treatment related toxicity . Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer . Participation investigational study within 4 week precede start study treatment . Clinically significant heart disease define NYHA class 3 4 heart disease . Chronic debilitate disease investigator feel might compromise study Participation . Evidence inadequately treat CNS metastasis . Major surgery within 4 week s1art study treatment without complete recovery . Known exist uncontrolled coagulopathy . Any following laboratory parameter v ) Abnormal hematological value ANC le 1500/mm3 , thrombocytopenia le 99,000. vi ) Impaired renal function serum creatinine great 1.5 ULN vii ) Serum bilirubin great 1.5xULN viii ) Albumin le 2.5mg/dl . Unwillingness give inform consent . Unwillingness participate inability comply protocol duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Liver</keyword>
	<keyword>hepatocellular</keyword>
	<keyword>Gem-Ox</keyword>
	<keyword>Cancer</keyword>
</DOC>